Ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 80, Issue 5, 2003, Pages 1309-1314

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN; BASIC FIBROBLAST GROWTH FACTOR; DEXTRAN; DIURETIC AGENT; DOPAMINE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FUROSEMIDE; GONADORELIN AGONIST; GONADOTROPIN; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUPRORELIN; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

AGE; ARTICLE; ASCITES; BODY WEIGHT; CAPILLARY PERMEABILITY; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION THERAPY; CORPUS LUTEUM; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ECTOPIC PREGNANCY; ESTRADIOL BLOOD LEVEL; FEMALE INFERTILITY; FLUID INTAKE; FLUID THERAPY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPOKALEMIA; INTENSIVE CARE; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; OUTPATIENT; OVARY DISEASE; OVARY FOLLICLE; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PARACENTESIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SUPEROVULATION; THROMBOEMBOLISM; VIRUS TRANSMISSION;

EID: 0242577340     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)02194-0     Document Type: Article

References (53)

1. Blankstein J., Shalev J., Saadon T., Kukia E.E., Rabinovici J., Pariente C., et al. Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles . Fertil Steril. 47:1987;597-602.
2. McArdle C., Siebel M., Hann L.E., Weinstein F., Taymor M. The diagnosis of ovarian hyperstimulation (OHS) the impact of ultrasound . Fertil Steril. 39:1983;464-467.
3. Pride S.M., James C.S.J., Yuen B.H. The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol. 8:1990;247-260.
4. Tollan A., Holst N., Forsdahl F., Fadnes H.O., Oian P., Maltau J.M. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol. 162:1990;554-558.
5. Goldsman M.P., Pedram A., Dominguez C.E., Ciuffardi I., Levin E., Asch R.H. Increased capillary permeability induced by human follicular fluid a hypothesis for an ovarian origin of the hyperstimulation syndrome . Fertil Steril. 63:1995;268-272.
6. Bergh P.A., Navot D. Ovarian hyperstimulation syndrome a review of pathophysiology . J Assist Reprod Genet. 9:1992;429-438.
7. Koninckx P.R., Heyns W., Verhoeven G., Van Baelen H., Lissens W.D., et al. Biochemical characterization of peritoneal fluid in women during the menstrual cycle. J Clin Endocrinol Metab. 51:1980;1239-1244.
8. Koninckx P.R., Renaer M., Brosens I.A. Origin of peritoneal fluid in women an ovarian exudation product . Br J Obstet Gynaecol. 87:1980;177-183.
9. Donnez J., Langerock S., Thomas K. Peritoneal fluid volume and 17β-estradiol and progesterone concentrations in ovulatory, anovulatory and postmenopausal women. Obstet Gynecol. 59:1982;687-692.
10. Sealey J.E., Atlas S.A., Glorioso N., Manapat H., Laragh J.H. Cyclical secretion of prorenin during the menstrual cycle synchronization with luteinizing hormone and progesterone . Proc Natl Acad Sci USA. 82:1985;8705-8709.
11. Derkx F.H., Alberda A.T., Zeilmaker G.H., Schalekamp M.A. High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 94:1987;4-9.
12. Lightman A., Tarlatzis B.C., Rzasa P.J., Culler M.D., Caride V.J., Negro-Vilar A.F., et al. The ovarian renin-angiotensin system renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid . Am J Obstet Gynecol. 156:1987;808-816.
13. Geva E., Jaffe R.B. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 74:2000;429-438.
14. Levin E.R., Rosen G.F., Cassidenti D.L., Yee B., Meldrum D., Wisot A., et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 102:1998;1978-1985.
15. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
16. Neulen J., Yan Z., Raczek S., Weindel K., Keek C., Weich H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells importance in ovarian hyperstimulation syndrome . J Clin Endocrinol Metab. 80:1995;1967-1971.
17. Pellicer A., Albert C., Mercader A., Bonilla-Musoles F., Remohi J., Simon C. The pathogenesis of ovarian hyperstimulation syndrome in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor . Fertil Steril. 71:1999;482-489.
18. Whelan J.G. 3rd, Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil Steril. 73:2000;883-896.
19. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor I in colorectal carcinoma. J Biol Chem. 271:1996;483-488.
20. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev. 18:1997;4-25.
21. Navot D., Relou A., Birkenfeld A., Rabinowitz R., Brzezinski A., Margalioth E.J. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 159:1988;210-215.
22. Delvigne A., Demoulin A., Smitz J., Donnez J., Koinckx P., Dhont M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization a Belgian multicentric study. I. Clinical and biological features . Hum Reprod. 8:1993;1353-1360.
23. MacDougall M.J., Tan S.L., Jacobs H.S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;597-600.
24. Buyalos R.P., Lee C.T. Polycystic ovary syndrome pathophysiology and outcome with in vitro fertilization . Fertil Steril. 65:1996;1-10.
25. Forman R.G., Frydman R., Egan D., Ross C., Barlow D.H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization a European series and a proposal for prevention . Fertil Steril. 53:1990;502-509.
26. Mizunuma H., Andoh K., Yamada K., Takagi T., Kamijo T., Ibuki Y. Prediction and prevention of ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified follicle-stimulating hormone therapy. Fertil Steril. 58:1992;46-50.
27. Mordel N., Schenker J.G. Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod. 8:1993;2009-2014.
28. Haning R.V. Jr, Austin C.W., Carlson I.H., Kuzma D.L., Shapiro S.S., Zweibel W.J. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril. 40:1983;31-36.
29. Enskog A., Henriksson M., Unander M., Nilsson L., Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 71:1999;808-814.
30. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome an update review . Obstet Gynecol Surv. 44:1989;430-440.
31. Zosmer A., Katz Z., Lancet M., Konichezky S., Schwartz-Shoham Z. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril. 47:1987;524-526.
32. Abramov Y., Elchalal U., Schenker J.G. Pulmonary manifestations of severe ovarian hyperstimulation syndrome a multicenter study . Fertil Steril. 71:1999;645-651.
33. Pattinson H.A., Hignett M., Dunphy B.C., Fleetham J.A. Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril. 62:1994;1192-1196.
34. Shaker A.G., Zosmer A., Dean N., Bekir J.S., Jacobs H.S., Tan S.L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. [see comments, Fertil Steril 1997;67:587-9.] Fertil Steril. 65:1996;992-996.
35. Ferraretti A.P., Gianaroli L., Magli C., Fortini D., Selman H.A., Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome efficiency and safety . Hum Reprod. 14:1999;1457-1460.
36. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment . Fertil Steril. 58:1992;249-261.
37. Borenstein R., Elhalah U., Lunenfeld B., Schwartz Z.S. Severe ovarian hyperstimulation syndrome a reevaluated therapeutic approach . Fertil Steril. 51:1989;791-795.
38. Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. [erratum appears in Fertil Steril 1990;54:957.] Fertil Steril. 53:1990;933-935.
39. Rizk B., Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 6:1991;1082-1087.
40. Rinaldi M.L., Spirtos N.J. Chest tube drainage of pleural effusion correcting abdominal ascites in a patient with severe ovarian hyperstimulation syndrome a case report . [comment Fertil Steril 1995;64:1228-9.] Fertil Steril. 63:1995;1114-1117.
41. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. [comments Hum Reprod 1992;7:1181.] Hum Reprod. 7:1992;180-183.
42. Reed A.P., Tausk H., Reynolds H. Anesthetic considerations for severe ovarian hyperstimulation syndrome. Anesthesiology. 73:1990;1275-1277.
43. Grochowski D., Wolczynski S., Kuczynski W., Domitrz J., Szamatowicz J., Szamatowicz M. Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol. 15:2001;234-238.
44. Al-Shawaf T., Zosmer A., Hussain S., Tozer A., Panay N., Wilson C., et al. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer a modified "coasting" strategy based on ultrasound for identification of high-risk patients . Hum Reprod. 16:2001;24-30.
45. Ulug U., Bahceci M., Erden H.F., Shalev E., Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod. 17:2002;310-313.
46. Lewitt N., Kol S., Manor D., Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome a case-control study . Hum Reprod. 11:1996;1399-1402.
47. Friedman C.I., Schmidt G.E., Chang F.E., Kim M.H. Severe ovarian hyperstimulation following follicular aspiration. Am J Obstet Gynecol. 150:1984;436-437.
48. Asch R.H., Ivery G., Goldsman M., Frederick J.L., Stone S.C., Balmaceda J.P. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. [comments Hum Reprod 1994;9:753-4 and Hum Reprod 1995;10:2750-2.] Hum Reprod. 8:1993;1015-1020.
49. Shoham Z., Weissman A., Barash A., Borenstein R., Schachter M., Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program a prospective, randomized, placebo-controlled study . Fertil Steril. 62:1994;137-142.
50. Shalev E., Giladi Y., Matilsky M., Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin a prospective study . Hum Reprod. 10:1995;1373-1376.
51. Ng E., Leader A., Claman P., Domingo M., Spence J.E. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. [comments Hum Reprod 1996;11:460-1.] Hum Reprod. 10:1995;807-810.
52. Ben-Chetrit A., Eldar-Geva T., Gal M., Huerta M., Mimom T., Algur N., et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme a randomized placebo-controlled trial . Hum Reprod. 16:2001;1880-1884.
53. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002;2:CD001302.